Home >  News >  February, 2014

Local Analgesic Reduces Post-Bariatric Opioids

Study explores Exparel's use in managing abdominal surgery pain.

Published: February 3, 2014

A multimodal pain management therapy that includes the non-opioid local analgesic Exparel lessens the need for post-op narcotics after bariatric surgery, according to a recent study.

For the study, Andras Sandor, MD, FACS, FASMBS, and colleagues at the Hallmark Health Center for Weight Management and Weight Loss Surgery in Medford, Mass., observed the pain management regimens of 90 patients undergoing laparoscopic bariatric procedures.

Half of the patients received a multimodal approach to post-op pain management, including Pacira Pharmaceutical's bupivacaine liposome injectable suspension drug, Exparel, infiltrated into the transversus abdominis plane (a process known as iTAP). The other half were given ketorolac and a lidocaine and bupivacaine/epinephrine combination perioperatively, and pain pumps of hydromorphone afterward.

Each group was allowed opioids at 2 days post-op. But the multimodal group consumed 60.7% fewer opioids. Additionally, they exhibited a greater return of bowel function at the 2-day mark. Dr. Sandor and his team presented their findings at the American Society for Metabolic & Bariatric Surgery's 2013 Obesity Week in November.

"The risks of opioids are pronounced in the bariatric population; utilizing a non-opioid platform with Exparel iTAP at its foundation contributed to decreasing both the amount of opioids needed and their resultant opioid-related adverse effects," says Dr. Sandor.

David Bernard


Also in the News...

Is Medicare Ready to Reimburse Outpatient Knee Replacement?
$22 Million Suit: 2 Dropped Instruments Left Patient Paralyzed
Study: UV Lamps Reduce Bacteria on Computer Keyboards by 99%
Report: Anesthesiologist's Blocks Blinded 5 Cataract Patients in One Morning
Hospital That Removed Kidney From Wrong Patient Blames Referring Physician
Medical Spa Liable for Woman's SSI Death Following Liposuction
Feds: CRNA Group Offered Free Drugs to ASCs for Exclusive Contracts

New to Outpatient Surgery Magazine?
Sign-up to continue reading this article.
Register Now
Have an account? Please log in:
Email Address:
  Remember my login on this computer

advertiser banner

Other Articles That May Interest You

Study: If Patients Fear Pain, They'll Feel Pain

Which Drug is Better For Post-op Pain Control?

Bupivacaine, at a price of about $2.80 per shot, or the liposomal bupivacaine formulation trade-named Exparel, at about $285 per vial? What we found may surprise you.

TJC Defends Its Pain Management Standards

The organization notes that opioid prescriptions were already on the rise before it released requirements for treating patients' pain.